A framework for comparing R&D productivity at big pharma companies vs. biotech startups

2020 ◽  
Vol 25 (4) ◽  
Author(s):  
Richard Murphey
Keyword(s):  
Research And Development ◽  
Early Stage ◽  
Preliminary Evidence ◽  
Pharmaceutical Companies ◽  
Small Companies ◽  
Recent Trends ◽  
D Investment

Biopharmaceutical research and development (R&D) productivity has been steadily declining for several decades.  Preliminary evidence suggests that this trend is stabilizing or reversing.  One hypothesis explaining this improvement in R&D productivity is that the industry has shifted early-stage R&D activity from large multinational pharmaceutical companies to more smaller venture-backed startup companies.  We examine recent trends in FDA approvals and biopharmaceutical R&D investment to develop a framework to evaluate whether small companies are more productive at R&D than larger companies.

The impact of research and development and marketing costs on the profitability of pharmaceutical companies of Tehran Stock Exchange using panel data 2001-2013

2016 ◽  
Vol 10 (4) ◽  
pp. 467-476 ◽  
Author(s):  
Yahya Bayazidi ◽  
Enayatollah Homaie Rad ◽  
Mehdi Mojahedian ◽  
Mehdi Toroski ◽  
Azita Nabizadeh ◽  
...  
Keyword(s):  
Panel Data ◽  
Research And Development ◽  
Stock Exchange ◽  
Random Effect ◽  
Patent Law ◽  
Pharmaceutical Companies ◽  
Content Type ◽  
Marketing Costs ◽  
The Impact ◽  
D Investment

Purpose The main aim of this study is to investigate the effects of marketing and costs and research and development (R&D) investments on profitability of pharmaceutical companies of Iran. Design/methodology/approach In this study, pharmaceutical companies that have been accepted in Tehran Stock Exchange until March 19, 2013 were investigated. Random-effect panel data estimator was used for this purpose. Findings The findings indicate that variables such as company size, capital-to-total asset ratio and debt-to-asset ratio have an effect on profitability. But, company life, advertising cost and R&D investment are ineffective on profitability. Originality/value Legal issues like not having patent law and pricing mechanism are reasons for the ineffective relationship between R&D and marketing costs and its effect on profitability of the Iran pharmaceutical industry.

scholarly journals European Option Based R&D Investment Decision Making under Uncertainties

2015 ◽  
Vol 2015 ◽  
pp. 1-6
Author(s):  
Qing Miao ◽  
Boyang Cao ◽  
Minghui Jiang
Keyword(s):  
Decision Making ◽  
Research And Development ◽  
Joint Venture ◽  
Investment Decision ◽  
Optimal Investment ◽  
European Option ◽  
Project Investment ◽  
Research Joint Venture ◽  
Investment Decision Making ◽  
D Investment

This paper establishes the payoff models of the European option for research and development (R&D) projects with two enterprises in a research joint venture (RJV). The models are used to assess the timing and payoffs of the R&D project investment under quantified uncertainties. After the option game, the two enterprises can make optimal investment decision for the R&D project investment in the RJV.

scholarly journals ORBIS (Open Research Biopharmaceutical Internships Support) – building bridges between academia and pharmaceutical industry to improve drug development

2020 ◽  
Vol 89 (1) ◽  
pp. e419
Author(s):  
Janina Lulek ◽  
Emilia Jakubowska ◽  
Sharon Davin ◽  
Aleksandra Dumicic Dumicic ◽  
Grzegorz Garbacz ◽  
...  
Keyword(s):  
Drug Delivery Systems ◽  
Early Stage ◽  
Dosage Forms ◽  
Pharmaceutical Companies ◽  
Drug Bioavailability ◽  
Horizon 2020 ◽  
Medicine Development ◽  
Research And Innovation ◽  
Open Research ◽  
Staff Exchange

Open Research Biopharmaceutical Internships Support (ORBIS) is an international, Horizon 2020 project funded by Maria Skłodowska-Curie Actions, Research and Innovation Staff Exchange (RISE) programme. Six academic institutions and four pharmaceutical companies from seven countries cooperate with the aim to improve the preclinical pathway of medicine development through increased Research and Development (R&D) productivity, especially focusing on processes and technologies which address the challenge of poor drug bioavailability. The RISE scheme supports secondments, meaning that early stage and experienced researchers are sent to consortium partner institutions to advance studies on pharmaceutical preformulation, dosage forms and drug delivery systems and methods of biopharmaceutical evaluation. The ORBIS project enables secondees to gain news skills and develop their competences in an international and intersectoral environment, strengthening the human capital and knowledge synergy in the European pharmaceutical R&D sector.

scholarly journals Tanggung Jawab Sosial Dan Risiko Sistematis: Efek Moderasi Dari Fleksibilitas Keuangan Dan Investasi Penelitian Dan Pengembangan

2021 ◽  
Vol 4 (2) ◽  
pp. 162-185
Author(s):  
Anita Anita ◽  
Lisa Lim
Keyword(s):  
Regression Analysis ◽  
Corporate Social Responsibility ◽  
Social Responsibility ◽  
Research And Development ◽  
Stock Prices ◽  
Systematic Risk ◽  
Financial Flexibility ◽  
Corporate Social ◽  
The Relationship ◽  
D Investment

The study is conducted with the aim of examining the effect of corporate social responsibility on systematic risk in companies listed on the IDX for the period of 2016-2020. This study adds financial flexibility and research and development investment as moderators which are still remain unexplored in Indonesia. This research is expected to be able to make investors consider social responsibility as a factor in making investment decisions. The data taken are stock prices, annual reports and sustainability reports which are secondary data. Data collection using purposive sampling method with certain criteria so that the number of samples in this study amounted to 43 companies. In testing the hypothesis using panel data regression analysis techniques with eviews. The results of the regression analysis show that the existence of corporate social responsibility has a significant positive effect on systematic risk. The moderating variable of financial flexibility does not affect the relationship between CSR and systematic risk. Then the research and development investment variables weaken the relationship between CSR and systematic risk. Therefore, management is expected to pay attention to R&D investment in making CSR policies. This study explains that R&D investment is one of the important roles in company sustainability.

PENGEMBANGAN MEDIA BELAJAR PJOK PADA MATERI SENAM LANTAI (ARTISTIK)

2020 ◽  
Vol 8 (2) ◽  
pp. 86
Author(s):  
Zulbahri Zulbahri ◽  
Yuni Astuti ◽  
Erianti . ◽  
Pitnawati . ◽  
Damrah .
Keyword(s):  
Research And Development ◽  
Small Group ◽  
Quantitative Data ◽  
Early Stage ◽  
Field Trials ◽  
Development Research ◽  
Initial Product ◽  
Initial Stage ◽  
Stage 4 ◽  
The Media

This research is motivated by the limited development of learning media for the subjects of Physical Education, Sports and Health on floor exercise (artistic) material, especially for schools in the regions. This study aims to produce a learning media product for students and students in learning gymnastics. The subjects or samples of this research were FIK UNP students who attended basic and advanced / learning gymnastics courses with a total of 12 people for small group subject trials and 15 people for field trials. The data used in this research are qualitative and quantitative data. Qualitative data in this study is data obtained through validation from material experts, media experts, while quantitative data in this study were obtained through assessment questionnaires which were analyzed with descriptive statistics.This research was conducted using "Research and Development" (Research and Development), namely the research method used to produce certain products. The model used as a reference is the Borg & Gall development research model with 10 developments, in this study the researcher adopted the following stages: 1) Preliminary Study (research and data collection). 2) Prepare a plan and analyze the media to be made. 3) Initial product development by producing learning media with validation by media experts and material experts. 4) Conduct small group trials. 5) Product Revisions. 6) Conduct field trials. 7) Revise the final product. For this early stage research, it has only arrived at the fourth stage (4), namely the initial stage validation by media experts and material experts. Research results in the form of learning media products for practical material with a score of 3.67 with good criteria and for media with a score of 3.3 with a fairly good category.

Three Views of a Train Wreck

2016 ◽  
Author(s):  
Michael Kinch
Keyword(s):  
Public Health ◽  
Research And Development ◽  
Venture Capital ◽  
Food Chain ◽  
Early Stage ◽  
Health Benefits ◽  
Federal Spending ◽  
Moore’S Law ◽  
Government Grants ◽  
Start Ups

Despite and arguably because of the enormous public health benefits arising from the introduction of new medicines, the industry is in the midst of crisis. We detail in this chapter the decline in research and development efficiency, which has been termed “Eroom's Law,” a playful inversion of the bettern known Moore's Law of Computing. An explanation of declining efficiency follows as is a brief summary of some remedies taken by many biopharmaceutical entities, including the abandonment of therapeutics targeting particularly difficult indications such as Alzheimer's disease and antibiotics. We also convey how the industry has developed into a sort of food chain, with smaller companies and government grants supporting the earliest stages of research, which are then acquired by medium-sized companies, which in turn are consolidated into large companies. This food chain is fundamentally in doubt based on shrinking Federal spending on research combined with a decline in venture capital support for early-stage start-ups.

Edible insects: cricket farming and processing as an emerging market

2020 ◽  
Vol 6 (2) ◽  
pp. 211-220 ◽  
Author(s):  
M. Reverberi
Keyword(s):  
Emerging Market ◽  
Farming Systems ◽  
Food Product ◽  
Small Companies ◽  
Food Ingredient ◽  
Business Operations ◽  
New Development ◽  
Recent Trends ◽  
Packaged Food ◽  
Online Shops

This article provides information on recent trends in cricket farming and processing in Asian and Western countries. Whilst eating insects collected from the wild has long been a common practice in many countries, farming and transforming insects into a food ingredient for packaged products is a new development. Particularly in North America and Europe, some new, small companies are transforming cricket (and mealworm) powder into packaged food (energy bars, pasta, and chips among the examples). Within this article, two contrasting farming systems are principally considered. On one hand is the Thai cricket farming model, based on micro-farms, in which the small farmers do not make the flour; this task instead being handled by specialised businesses. On the other hand, is the western farming model, in which farms are large, and the flour is produced by the very same factory-farm. Examples of this model are found in the Netherlands (Protifarm) and Canada (Entomofarm). Since insect powders (flour) in packaged foods represent a new category of food product, little market data and/or surveys are available. The products are often sold on small online shops, within the context of an informal business operations. As a consequence, some of the information in this article comes from informal sources or the direct experience of the author.

scholarly journals WIPO Re:Search—A Platform for Product-Centered Cross-Sector Partnerships for the Elimination of Schistosomiasis

2019 ◽  
Vol 4 (1) ◽  
pp. 11 ◽  
Author(s):  
Callie J. Weber ◽  
Joseph Hargan-Calvopiña ◽  
Katy M. Graef ◽  
Cathyryne K. Manner ◽  
Jennifer Dent
Keyword(s):  
Chronic Disease ◽  
Global Health ◽  
Product Development ◽  
Research And Development ◽  
Mass Drug Administration ◽  
Early Stage ◽  
Neglected Diseases ◽  
Non Profit ◽  
For Profit ◽  
Two Sectors

Schistosomiasis is an acute and chronic disease that affects over 200 million people worldwide, and with over 700 million people estimated to be at risk of contracting this disease, it is a pressing issue in global health. However, research and development (R&D) to develop new approaches to preventing, diagnosing, and treating schistosomiasis has been relatively limited. Praziquantel, a drug developed in the 1970s, is the only agent used in schistosomiasis mass drug administration (MDA) campaigns, indicating a critical need for a diversified therapeutic pipeline. Further, gaps in the vaccine and diagnostic pipelines demonstrate a need for early-stage innovation in all areas of schistosomiasis product R&D. As a platform for public-private partnerships (PPPs), the WIPO Re:Search consortium engages the private sector in early-stage R&D for neglected diseases by forging mutually beneficial collaborations and facilitating the sharing of intellectual property (IP) assets between the for-profit and academic/non-profit sectors. The Consortium connects people, resources, and ideas to fill gaps in neglected disease product development pipelines by leveraging the strengths of these two sectors. Using WIPO Re:Search as an example, this article highlights the opportunities for the PPP model to play a key role in the elimination of schistosomiasis.

Sign in / Sign up

Export Citation Format

Share Document